Search

Your search keyword '"OVERALL survival"' showing total 10 results
Start Over Descriptor "OVERALL survival" Topic antineoplastic agents Publication Year Range Last 50 years Publisher mjh life sciences
10 results on '"OVERALL survival"'

1. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.

Author

Cookson, Michael S.

Subjects
*NON-muscle invasive bladder cancer, *GENE therapy, *UROLOGY, *BCG vaccines, *IMMUNOTHERAPY, *ANTINEOPLASTIC agents, *DISEASE management, *TREATMENT effectiveness, *SEVERITY of illness index, *IMMUNE checkpoint inhibitors, *OVERALL survival, BLADDER tumors
Abstract

The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.

Published
2024

2. Evaluating the Role of Neoadjuvant Sacituzumab Govitecan in Bladder Cancer.

Author

Inman, Silas

Subjects
THERAPEUTIC use of antineoplastic agents, BLADDER tumors, DRUG toxicity, PATIENT safety, DRUG side effects, ENZYME inhibitors, ANTINEOPLASTIC agents, TUMOR markers, GENETIC polymorphisms, DRUG approval, COMBINED modality therapy, QUALITY of life, OVERALL survival, PHARMACODYNAMICS
Published
2024

3. FDA Grants Full Approval to Elahere.

Subjects
THERAPEUTIC use of antineoplastic agents, FOLIC acid metabolism, THERAPEUTIC use of monoclonal antibodies, WOMEN, COST effectiveness, ANTINEOPLASTIC agents, OVARIAN tumors, CANCER patients, EYE care, DRUG approval, PHARMACY information services, MONOCLONAL antibodies, DRUG monitoring, DRUG efficacy, FALLOPIAN tube diseases, OVARIAN epithelial cancer, PERITONEUM tumors, PROGRESSION-free survival, CELL receptors, OVERALL survival, DRUG labeling
Abstract

The article focuses on the U.S. Food and Drug Administration (FDA) has approved Elahere for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients with prior systemic treatment. It reports that the approval was based on data from the confirmatory phase 3 MIRASOL trial, showing a reduction in death and cancer progression risk. Elahere, developed by ImmunoGen and acquired by AbbVie, targets folate receptor alpha.

Published
2024

5. Ibrutinib, Venetoclax Trial Boosts PFS in MCL.

Author

Sava, Jordyn

Subjects
NON-Hodgkin's lymphoma, CANCER relapse, PATIENT safety, ANTINEOPLASTIC agents, PROTEIN-tyrosine kinase inhibitors, PROGRESSION-free survival, OVERALL survival, DRUG tolerance, PHARMACODYNAMICS
Published
2024

6. Ongoing Data Support Frontline Triplet in NSCLC.

Author

Berberabe, Tony

Subjects
THERAPEUTIC use of antineoplastic agents, SURVIVAL rate, ANTINEOPLASTIC agents, CONFERENCES & conventions, DESCRIPTIVE statistics, TREATMENT duration, TREATMENT effectiveness, CANCER chemotherapy, LUNG cancer, GENETIC mutation, OVERALL survival
Published
2024

7. FDA Withdraws Approval of Pepaxto in Multiple Myeloma.

Author

Myshko, Denise

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG approval, PRODUCT recall, DEXAMETHASONE, ANTINEOPLASTIC agents, MULTIPLE myeloma, OVERALL survival
Abstract

The article focuses on the U.S. Food and Drug Administration' (FDA) withdrawal of approval for Pepaxto in treating multiple myeloma due to the failure of its confirmatory study to demonstrate clinical benefit and safety. Topics discussed include the timeline of events leading to the withdrawal, the concerns raised by regulators regarding the drug's efficacy and safety, and Oncopeptides' response to the decision.

Published
2024

8. Alectinib (Alecensa).

Subjects
PATIENT safety, ANTINEOPLASTIC agents, CANCER chemotherapy, DRUG approval, LUNG cancer, PROGRESSION-free survival, OVERALL survival
Published
2024

9. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer

Author

Christina Wu, Tanios Bekaii-Saab, Jeremy Clifton Jones, Kristen K. Ciombor, and John H. Strickler

Subjects
Proto-Oncogene Proteins B-raf, Oncology, Cancer Research, medicine.medical_specialty, Receptor, ErbB-2, Colorectal cancer, MEDLINE, Antineoplastic Agents, Disease, Circulating Tumor DNA, Proto-Oncogene Proteins p21(ras), Internal medicine, medicine, Overall survival, Humans, Malignant cells, In patient, Molecular Targeted Therapy, Neoplasm Metastasis, business.industry, Therapeutic resistance, medicine.disease, ErbB Receptors, Drug Resistance, Neoplasm, Novel agents, Colorectal Neoplasms, business, Cell-Free Nucleic Acids
Abstract

Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide. In the mid-1980s, the median overall survival (OS) for patients with mCRC ranged from 10 to 12 months from the time of initial diagnosis. In more recent studies, this median has more than doubled and is commonly reported at more than 25 to 30 months. These improvements are due, in large part, to the introduction of multiple novel agents during the last 3 decades. Despite these improvements, however, nearly all patients treated with palliative chemotherapy will eventually develop resistance and ultimately succumb to progression of metastatic disease. Understanding the mechanisms by which malignant cells evade treatment could unlock novel therapeutic strategies that overcome resistance and improve survival. In this review, we will discuss some of the drivers of therapeutic resistance in patients with mCRC and present some novel strategies to overcome resistance.

Published
2021

10. Nivolumab (Opdivo).

Subjects
THERAPEUTIC use of antineoplastic agents, BLADDER tumors, CISPLATIN, ANTINEOPLASTIC agents, PROGRAMMED death-ligand 1, TRANSITIONAL cell carcinoma, CANCER chemotherapy, DRUG approval, METASTASIS, NIVOLUMAB, PROGRESSION-free survival, OVERALL survival
Published
2024

Catalog

Books, media, physical & digital resources
See catalog results